PubMed ID,Title,Publication Date,All Authors,All Affiliations,Authors Emails
40086733,Redefining Clinical Trial Strategic Design to Support Drug Approval in Medical Oncology.,2025,"G Antonarelli, J M Pérez-García, M Gion, H Rugo, P Schmid, A Bardia, S Hurvitz, N Harbeck, S M Tolaney, G Curigliano, A Llombart-Cussac, J Cortés","Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy.; Medica Scientia Innovation Research (MEDSIR), Barcelona (Spain) and Ridgewood (New Jersey, USA); International Breast Cancer Center (IBCC), Pangaea Oncology, Quirón Group, Barcelona, Spain.; Hospital Universitario Ramón y Cajal, Madrid, Spain.; Department of Medicine, University of California San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA.; Barts Cancer Institute, Queen Mary University of London, London, UK.; University of California Los Angeles (UCLA), Los Angeles, CA, USA.; Fred Hutchinson Cancer Center, University of Washington School of Medicine, Seattle, WA, USA.; Breast Center, Department of Obstetrics and Gynecology and CCC Munich, LMU University Hospital, Munich, Germany.; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Division of New Drugs and Early Drug Development for Innovative Therapies, European Institute of Oncology, IRCCS, Milan, Italy; Department of Oncology and Haematology (DIPO), University of Milan, Milan, Italy.; Medica Scientia Innovation Research (MEDSIR), Barcelona (Spain) and Ridgewood (New Jersey, USA); Arnau de Vilanova Hospital, Universidad Católica de Valencia, Valencia, Spain.; Medica Scientia Innovation Research (MEDSIR), Barcelona (Spain) and Ridgewood (New Jersey, USA); International Breast Cancer Center (IBCC), Pangaea Oncology, Quirón Group, Barcelona, Spain; Universidad Europea de Madrid, Faculty of Biomedical and Health Sciences, Department of Medicine, Madrid, Spain; IOB Madrid, Institute of Oncology, Hospital Beata María Ana, Madrid, Spain; Oncology Department, Hospital Universitario Torrejón, Ribera Group, Madrid, Spain. Electronic address: javier.cortes@maj3.health.",javier.cortes@maj3.health
40085988,Metabolism profiles of tannins in Phyllanthus emblica L. and its immunotherapeutic potential against hepatocellular carcinoma by re-educating tumor microenvironment.,2025,"Zihao Chang, Zhaohui Wang, Yinxin Chen, Yuqi Liu, Ye Gao, Yitong Cui, Le Wang, Yue Liu, Ruiyang Cheng, Runping Liu, Lanzhen Zhang","School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, PR China.; School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, PR China.; School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, PR China.; School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, PR China.; School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, PR China.; School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, PR China.; School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, PR China.; School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, PR China.; Institute of Chinese Materia Medica, China Academy of Chinese Medical Sciences, Beijing 100700, PR China. Electronic address: rycheng@icmm.ac.cn.; School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, PR China. Electronic address: liurunping01@hotmail.com.; School of Chinese Pharmacy, Beijing University of Chinese Medicine, Beijing 102488, PR China. Electronic address: zhanglanzhen01@126.com.",rycheng@icmm.ac.cn; liurunping01@hotmail.com; zhanglanzhen01@126.com
40084274,"Designing novel cabozantinib analogues as p-glycoprotein inhibitors to target cancer cell resistance using molecular docking study, ADMET screening, bioisosteric approach, and molecular dynamics simulations.",2025,"Gajendra Singh Thakur, Ajay Kumar Gupta, Dipti Pal, Yogesh Vaishnav, Neeraj Kumar, Sivakumar Annadurai, Sanmati Kumar Jain","Drug Discovery and Research Laboratory, Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, Chhattisgarh, India.; Drug Discovery and Research Laboratory, Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, Chhattisgarh, India.; Drug Discovery and Research Laboratory, Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, Chhattisgarh, India.; Drug Discovery and Research Laboratory, Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, Chhattisgarh, India.; Department of Pharmaceutical Chemistry, Bhupal Nobles' College of Pharmacy, Udaipur, Rajasthan, India.; Department of Pharmacognosy, College of Pharmacy, King Khalid University, Abha, Saudi Arabia.; Drug Discovery and Research Laboratory, Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, Chhattisgarh, India.",N/A
40084273,Discovery and preclinical development of a SdAb-based CAR-T technology for targeting CD33 in AML.,2025,"Franco Bernasconi-Bisio, Eva Molina, Vianca Ibarra, Inés Ibáñez-Sala, Federica Rochira, Patricia Jauregui, Saray Rodríguez-Diaz, Rebeca Martínez-Turrillas, Iñigo Azagra-Barber, Nuria Gómez-Cebrián, Juan José Lasarte, Leonor Puchades-Carrasco, Lucía Vanrell, Juan Roberto Rodríguez-Madoz, Felipe Prósper, Antonio Pineda-Lucena","Therapeutic Innovation Program, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Therapeutic Innovation Program, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Therapeutic Innovation Program, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Therapeutic Innovation Program, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Therapeutic Innovation Program, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, 31008 Pamplona, Spain.; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, 31008 Pamplona, Spain.; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, 31008 Pamplona, Spain.; Therapeutic Innovation Program, Cima Universidad de Navarra, 31008 Pamplona, Spain.; Drug Discovery Unit, Instituto de Investigación Sanitaria La Fe (IIS La Fe), 46026 Valencia, Spain.; Immunology and Immunotherapy Program, Cima Universidad de Navarra, IdiSNA, 31008 Pamplona, Spain.; Drug Discovery Unit, Instituto de Investigación Sanitaria La Fe (IIS La Fe), 46026 Valencia, Spain.; Nanogrow Biotech, Montevideo 11500, Uruguay.; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, 31008 Pamplona, Spain.; Hemato-Oncology Program, Cima Universidad de Navarra, IdiSNA, 31008 Pamplona, Spain.; Therapeutic Innovation Program, Cima Universidad de Navarra, 31008 Pamplona, Spain.",N/A
40083703,Regulated Cell Death in Lenvatinib Resistance of Hepatocellular Carcinoma: from Molecular Mechanisms to Therapeutic Strategies.,2025,"Ronggao Chen, Xin Hu, Yingchen Huang, Yao Jiang, Guanrong Chen, Qiaonan Shan, Xiao Xu, Shusen Zheng","Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.; Zhejiang University School of Medicine, Hangzhou 310058, China.; The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China.; School of Clinical Medicine, Hangzhou Medical College, Hangzhou 310059, China.; The Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou 310053, China.; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.; NHC Key Laboratory of Combined Multi-organ Transplantation, Hangzhou 310003, China.; Division of Hepatobiliary and Pancreatic Surgery, Department of Surgery, First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310003, China.",N/A
